IBS-C is not just constipation. It is a biopsychosocial disorder of gut-brain communication — with measurable pathology in visceral sensation, motility, and neural signaling. Here is what the evidence actually says.
The single most important distinction between IBS with constipation (IBS-C) and simple constipation is abdominal pain. In IBS, pain is not a side effect of constipation — it is the defining feature. Slow transit alone, without associated pain, is a different condition with a different mechanism and different treatment approach.
Diagnosis of IBS requires all of the following, per the Rome IV consensus (2016):
Subtyping uses the Bristol Stool Scale on days with abnormal stool consistency. IBS-C is defined as:
IBS-C should be distinguished from functional constipation (no pain criterion), dyssynergic defecation (pelvic floor coordination problem, diagnosed by anorectal manometry), and slow-transit constipation (diagnosed by colon transit study). Structural causes — colorectal cancer, inflammatory bowel disease, celiac disease, hypothyroidism — should be excluded before a functional diagnosis is made.
IBS-C is not a psychological disorder, and it is not purely a motility disorder. It is best understood as a disorder of gut-brain interaction — with multiple converging mechanisms, each measurable and each targetable.
IBS patients have a measurably lower pain threshold to rectal distension compared to healthy controls. This is quantified using a barostat — a device that inflates a balloon in the rectum at controlled pressures. IBS patients report pain at pressures that healthy subjects describe as mild discomfort or do not perceive at all.
The mechanism involves sensitized afferent sensory nerves expressing TRPV1 and TRPV4 channels, which lower the activation threshold for pain signaling. This is peripheral sensitization feeding into central sensitization — the spinal cord and brain amplify incoming gut signals. The pain in IBS-C is real, measurable, and neurologically explicable. It is not imagined.
Between meals, the small intestine runs a housekeeping program called the migrating motor complex (MMC) — a cyclical wave of contractions that sweeps undigested material toward the colon approximately every 90 minutes. In IBS-C, MMC activity is abnormal. Propulsive colonic contractions are reduced, contributing to slow transit and the accumulation of hard, dry stool. This is not the whole story — motility changes alone do not explain the pain — but they are a real and measurable component.
The gut and brain communicate via the enteric nervous system, vagus nerve, immune signaling, and the hypothalamic-pituitary-adrenal (HPA) axis. This is a genuinely bidirectional circuit:
Approximately 10% of people who experience acute infectious gastroenteritis go on to develop IBS — a well-documented phenomenon called post-infectious IBS. The most common bacterial triggers are Campylobacter and Salmonella. The mechanism is not ongoing infection but persistent consequences: intestinal permeability increases after the pathogen is cleared, immune activation continues, and — critically — enterochromaffin cells in the small intestine (which produce serotonin) appear to be damaged by the acute infection.
Ninety-five percent of the body's total serotonin is produced in the GI tract by enterochromaffin cells. This gut serotonin does not enter the bloodstream and act on the brain — it acts locally, regulating peristalsis, fluid secretion, and pain modulation. In IBS-C, 5-HT (serotonin) signaling is abnormal: serotonin transporter (SERT) expression is reduced, disrupting the normal re-uptake and clearance of serotonin after it is released. The net effect is dysregulated peristalsis and altered visceral pain processing. This is why medications targeting serotonin signaling — and even SSRIs — can have direct gut effects in IBS patients.
The low FODMAP diet — developed by Professor Peter Gibson and Dr. Sue Shepherd at Monash University in Melbourne — is currently the dietary intervention with the strongest evidence base for IBS symptom reduction. A 2021 Cochrane review found that 70-80% of IBS patients respond to the protocol.
FODMAP stands for Fermentable Oligo-, Di-, Monosaccharides And Polyols — a collection of short-chain carbohydrates that share two properties that make them problematic in IBS:
The low FODMAP diet is not a permanent elimination diet. It is a diagnostic and therapeutic tool with three defined phases:
| Category | High FODMAP — Avoid | Low FODMAP — Safe |
|---|---|---|
| Grains | Wheat, rye, barley (fructans) | Rice, oats, quinoa, corn, potatoes, sourdough spelt |
| Vegetables — Alliums | Onion, garlic, leek, shallots (fructans — highest risk) | Garlic-infused oil (FODMAP stays in water phase), chives, spring onion (green tops only) |
| Vegetables — Other | Cauliflower, mushrooms, asparagus, artichoke, beetroot (polyols or GOS) | Carrots, cucumber, lettuce, spinach, zucchini, eggplant, bok choy, bell peppers, tomatoes |
| Fruits | Apples, pears, mangoes, watermelon, cherries, peaches (excess fructose or polyols) | Bananas (firm), blueberries, strawberries, grapes, oranges, kiwi, pineapple (in servings) |
| Dairy | Milk, yogurt, soft cheeses, ice cream (lactose) | Lactose-free milk and yogurt, hard cheeses (cheddar, parmesan, brie, camembert), butter |
| Legumes | Lentils, chickpeas, kidney beans, black beans (GOS — galactooligosaccharides) | Canned and rinsed chickpeas (¼ cup), firm tofu, tempeh |
| Nuts & Seeds | Cashews, pistachios (GOS/fructans in large amounts) | Macadamias, peanuts, pecans, walnuts, pumpkin seeds, sesame seeds (in servings) |
| Proteins | Processed meats with additives, marinated meats with garlic/onion | Plain chicken, beef, pork, fish, seafood, eggs — all naturally FODMAP-free |
| Sweeteners | Honey, agave, high-fructose corn syrup, sorbitol, mannitol, xylitol | Maple syrup, white/brown sugar, stevia, glucose |
Note: FODMAP thresholds are portion-dependent. The Monash University FODMAP app provides current certified serving sizes and is considered the gold standard reference.
Linaclotide is a synthetic 14-amino-acid peptide that works as a guanylate cyclase-C (GC-C) receptor agonist on intestinal epithelial cells. This is a highly specific mechanism with a dual therapeutic effect that makes it uniquely suited to IBS-C:
Linaclotide is FDA-approved specifically for IBS-C at 290 mcg once daily (taken on an empty stomach, 30 minutes before the first meal). A 72 mcg dose is separately approved for chronic idiopathic constipation (without the pain component). Across multiple phase 3 trials, NNT for composite IBS-C endpoint (both pain and bowel symptom improvement) is approximately 5-7. The most common side effect is diarrhea, which is dose-dependent and typically leads to dose reduction rather than discontinuation.
Lubiprostone (Amitiza 8 mcg twice daily) activates type-2 chloride channels on intestinal epithelial cells — FDA-approved for IBS-C in women 18 and older. Evidence in men is less robust. Plecanatide (Trulance) shares linaclotide's GC-C mechanism with a slightly different pH-activation profile; it is approved for chronic constipation and IBS-C.
Low-dose TCAs — particularly amitriptyline and nortriptyline at 10-25 mg at night — are considered first-line neuromodulator therapy for IBS-C with significant pain, per multiple gastroenterology society guidelines. Their mechanism in IBS is entirely distinct from their antidepressant effect:
NNT for global IBS symptom relief with TCAs is approximately 4 across meta-analyses. Doses used for IBS (10-25 mg) are substantially lower than antidepressant doses (75-150 mg), and sedation is the most common complaint — for which nortriptyline (slightly less sedating than amitriptyline) is often preferred.
Selective serotonin reuptake inhibitors have a more limited role in IBS-C than in IBS-D but can improve global IBS symptoms — particularly anxiety and hypervigilance components — in some patients. They may also weakly accelerate gut transit. Evidence is less consistent than for TCAs. They are considered when anxiety co-morbidity is prominent or when TCAs are poorly tolerated.
Gut-directed hypnotherapy has the highest-quality psychotherapy evidence for IBS of any psychological intervention. The landmark Whorwell study (2006) — and multiple replications — demonstrated that a 12-session structured hypnotherapy protocol produced symptom improvement in approximately 80% of IBS patients, with effects maintained at 5-year follow-up. The mechanism is believed to involve modulation of gut-brain afferent signaling, reduced visceral hypersensitivity, and normalization of autonomic gut responses. Rome Foundation guidelines support gut-directed hypnotherapy for moderate-to-severe IBS.
IBS-specific CBT — distinct from general CBT — targets the catastrophizing, hypervigilance, and pain-avoidance behaviors that amplify IBS symptoms through the gut-brain loop. Multiple RCTs show significant global symptom reduction. Digital CBT programs (including Mahana Therapeutics, FDA-cleared as a prescription digital therapeutic for IBS) have expanded access. Rome Foundation guidelines recommend psychological therapies for moderate-to-severe IBS alongside medical management.
General probiotic claims for IBS are not supported. Strain specificity is critical. Bifidobacterium longum 35624 — the specific strain in Align — has the most consistent RCT evidence for IBS, with multiple trials showing reductions in abdominal pain, bloating, and overall symptom severity. The mechanism is believed to involve immune modulation at the gut mucosal level rather than colonization. Note that probiotic effects require continued use — benefits are typically lost within weeks of discontinuation.
IBS-C rarely resolves with a single intervention. The strongest outcomes come from layered treatment — addressing diet, the gut microbiome, and gut-brain neurology in sequence, escalating based on response. This protocol reflects current Rome Foundation and ACG (American College of Gastroenterology) guidance.
Two evidence-aligned resources worth having:
What is the difference between IBS-C and regular constipation?
The key distinguishing feature of IBS-C is abdominal pain associated with constipation. Regular constipation is slow transit without the pain component. Rome IV criteria require recurrent abdominal pain at least 1 day per week for at least 3 months, associated with changes in bowel habits. Pain is central to IBS — not a side effect.
How does the low FODMAP diet work for IBS-C?
FODMAPs (Fermentable Oligo-, Di-, Monosaccharides And Polyols) are poorly absorbed short-chain carbohydrates that draw osmotic water into the intestine and undergo rapid bacterial fermentation, producing gas, bloating, and pain. Eliminating high-FODMAP foods for 2-6 weeks, then systematically reintroducing them, identifies personal triggers. Around 70-80% of IBS patients respond to the Monash University protocol.
What is linaclotide and how does it treat IBS-C?
Linaclotide (Linzess) is a guanylate cyclase-C (GC-C) agonist. It increases cGMP inside intestinal cells, driving chloride and water secretion into the bowel lumen (improving constipation) while simultaneously decreasing visceral afferent nerve firing (reducing pain). It is FDA-approved specifically for IBS-C at 290 mcg daily. Number-needed-to-treat is 5-7 across multiple phase 3 trials.
Can anxiety cause IBS-C?
The relationship is bidirectional, not causal. Stress and anxiety trigger CRH release, which activates mast cell degranulation, increasing mucosal permeability and sensory nerve activation — amplifying pain and motility changes. But IBS itself also drives anxiety through chronic pain and unpredictability. The gut-brain axis is a two-way neural circuit. IBS-C is not 'in your head' — it has measurable physiological pathology in both directions.
What probiotic is best for IBS-C?
Bifidobacterium longum 35624 (sold as Align) has the strongest RCT evidence for IBS specifically, with multiple trials showing reductions in abdominal pain and bloating. Strain specificity matters — general probiotics do not have the same evidence base.
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.